Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EarlySense Ltd.

www.earlysense.com

Latest From Hologic Inc.

AxoGen Creates New Chief Commercial Officer Role

Axogen has hired Boston Scientific alumnus Jon Gingrich to the newly created role of chief commercial officer (CCO). Gingrich will oversee development and execution of the company's sales and marketing development as it expands its portfolio of nerve regeneration products.

Appointments Regenerative Medicine

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017

Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Medical Device In Vitro Diagnostics

US Approvals Analysis: Biotronik Making Its Interventional Mark

The German-headquartered firm is making a play to enter the US vascular intervention market, with two stents approved by FDA under original PMAs in the first quarter of 2017. Cardiovascular devices, in general, have gained the most novel-device approvals so far this year, followed by IVDs. Check out more from a Q1 look at US FDA approvals and clearances monitored by Medtech Insight's Approvals Tracker.

Cardiology Cancer

iCAD Touts PMA-Approved Tool As Time-Saver For 3D Breast Assessment

iCAD won US FDA approval for its PowerLook Tomo Detection computer-aided detection tool for the growing field of digital breast 3D tomosynthesis product. It's intended to address a key complaint by radiologists with tomosynthesis: the long time it takes to read 3D, compared to 2D exams.

Cancer Diagnostic Imaging
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Biosensors
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • EarlySense Ltd.
  • Senior Management
  • Avner Halperin, CEO
    Dov Gal, CFO
    Guy Meger, VP, R&D
    Yfat Scialom, VP, International Sales & Mktg.
  • Contact Info
  • EarlySense Ltd.
    Phone: (972) 3.752.2330
    12 Tsvi St.
    Ramat Gan, MA 5250429
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register